Edward V. Nunes mainly investigates Psychiatry, Substance abuse, Placebo, Internal medicine and Randomized controlled trial. His Psychiatry study incorporates themes from Clinical trial and Clinical psychology. Edward V. Nunes has included themes like Alcohol dependence, Contingency management, Public health, Mental health and Cognitive therapy in his Substance abuse study.
His research in Placebo intersects with topics in Imipramine, Anesthesia, Pharmacotherapy and Discontinuation. In his study, Clinical Global Impression is inextricably linked to Placebo-controlled study, which falls within the broad field of Internal medicine. As a member of one scientific family, Edward V. Nunes mostly works in the field of Randomized controlled trial, focusing on Attention deficit hyperactivity disorder and, on occasion, Bupropion and Cognitive behavioral therapy.
His primary scientific interests are in Psychiatry, Clinical psychology, Substance abuse, Randomized controlled trial and Internal medicine. His work carried out in the field of Psychiatry brings together such families of science as Placebo and Clinical trial. His Clinical psychology research is multidisciplinary, relying on both Psychological intervention, Psychosocial, Cognition, Anxiety and Comorbidity.
His Substance abuse study combines topics from a wide range of disciplines, such as Methadone, Epidemiology, Public health, Mental health and Cognitive therapy. The concepts of his Randomized controlled trial study are interwoven with issues in Buprenorphine, Opioid use disorder, Intervention and Naltrexone. The Internal medicine study combines topics in areas such as Relapse prevention and Drug.
Edward V. Nunes spends much of his time researching Opioid use disorder, Buprenorphine, Randomized controlled trial, Naltrexone and Opioid. Edward V. Nunes interconnects Opioid overdose, Psychiatry and Buprenorphine/naloxone in the investigation of issues within Opioid use disorder. Psychiatry and Extramural are two areas of study in which Edward V. Nunes engages in interdisciplinary research.
His Buprenorphine research includes themes of Methadone, Psychological intervention, Logistic regression, Intensive care medicine and Substance abuse. His study in Substance abuse is interdisciplinary in nature, drawing from both Discontinuation and Substance use. The study incorporates disciplines such as Placebo and Abstinence in addition to Internal medicine.
His primary areas of investigation include Opioid use disorder, Buprenorphine, Methadone, Naltrexone and Randomized controlled trial. Opioid use disorder is a primary field of his research addressed under Internal medicine. His Internal medicine study combines topics in areas such as Crossover study and Placebo-controlled study.
As a part of the same scientific family, Edward V. Nunes mostly works in the field of Methadone, focusing on Psychological intervention and, on occasion, Psychosocial, Mood, Clinical psychology and Craving. His Naltrexone research is under the purview of Opioid. His biological study spans a wide range of topics, including Psychotherapist, Mindfulness, Anesthesia and Addiction.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis.
Edward V. Nunes;Frances R. Levin.
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial
Evgeny Krupitsky;Edward V Nunes;Walter Ling;Ari Illeperuma.
The Lancet (2011)
Cognitive deficits predict low treatment retention in cocaine dependent patients
Efrat Aharonovich;Deborah S. Hasin;Adam C. Brooks;Xinhua Liu.
Drug and Alcohol Dependence (2006)
Effects of major depression on remission and relapse of substance dependence.
Deborah Hasin;Xinhua Liu;Edward Nunes;Steven McCloud.
Archives of General Psychiatry (2002)
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
Joshua D Lee;Edward V Nunes;Patricia Novo;Ken Bachrach.
The Lancet (2017)
Rates of Psychiatric Comorbidity Among U.S. Residents with Lifetime Cannabis Dependence
Vito Agosti;Edward Nunes;Frances Levin.
American Journal of Drug and Alcohol Abuse (2002)
Cognitive impairment, retention and abstinence among cocaine abusers in cognitive-behavioral treatment
Efrat Aharonovich;Edward Nunes;Deborah Hasin.
Drug and Alcohol Dependence (2003)
Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design.
Stephen J. Donovan;Jonathan W. Stewart;Edward V. Nunes;Frederic M. Quitkin.
American Journal of Psychiatry (2000)
Do treatment improvements in PTSD severity affect substance use outcomes? A secondary analysis from a randomized clinical trial in NIDA's Clinical Trials Network.
Denise A. Hien;Huiping Jiang;Aimee N.C. Campbell;Mei-Chen Hu.
American Journal of Psychiatry (2010)
Multisite randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders.
Denise A. Hien;Elizabeth A. Wells;Huiping Jiang;Lourdes Suarez-Morales.
Journal of Consulting and Clinical Psychology (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: